BioSpace News Archive

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “The Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company appointed Mr. Andrew (“Andy”) Gornell Ballou as Vice President of Investor Relations.

Researchers from the Intermountain Healthcare Heart Institute are launching one of the largest and most ambitious research initiatives ever undertaken in the state of Utah to test a new standard of care to better identify and treat people at risk of having a heart attack – and to potentially stop it before they ever have one.

RhoVac AB announces, on 29th October, 2019, that the company has received approval from FIMEA for starting the clinical phase IIb study in prostate cancer, a multicenter study entitled RhoVac-002 The phase IIb study is an international, multicenter study, which is expected to recruit more than 175 patients in six European countries, as well as in the United States.

Krueger-Gilbert Health Physics executive to lead accounting and finance for Apex Physics Partners.

Lantern Pharma, a clinical stage oncology biotech leveraging A.I., machine learning (ML) and genomics, announced today that it has selected Reprocell to provide preclinical screening and drug sensitivity work for its portfolio of oncology drugs

Ceapro Inc. announced that the European and U.S. Patent and Trademark Offices have issued the Company European Patent No. 2411527 and U.S. Patent No. 10,334,869 entitled, “Method For Increasing Concentration of Avenanthramides in Oats,” related to the production of its value-driver product, avenanthramides, utilizing a malting technology in-licensed from Agriculture and Agri-Food Canada.

CB2 Insights Inc. (CSE:CBII; OTCQB: CBIIF) (“CB2”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced it has entered into a technology and multi-phase research agreement with VIVO Cannabis Inc.